| Literature DB >> 22666551 |
Ignacio Farro1, Daniel Bia, Yanina Zócalo, Juan Torrado, Federico Farro, Lucía Florio, Alicia Olascoaga, Walter Alallón, Ricardo Lluberas, Ricardo L Armentano.
Abstract
Carotid-femoral pulse wave velocity (PWV) has emerged as the gold standard for non-invasive evaluation of aortic stiffness; absence of standardized methodologies of study and lack of normal and reference values have limited a wider clinical implementation. This work was carried out in a Uruguayan (South American) population in order to characterize normal, reference, and threshold levels of PWV considering normal age-related changes in PWV and the prevailing blood pressure level during the study. A conservative approach was used, and we excluded symptomatic subjects; subjects with history of cardiovascular (CV) disease, diabetes mellitus or renal failure; subjects with traditional CV risk factors (other than age and gender); asymptomatic subjects with atherosclerotic plaques in carotid arteries; patients taking anti-hypertensives or lipid-lowering medications. The included subjects (n = 429) were categorized according to the age decade and the blood pressure levels (at study time). All subjects represented the "reference population"; the group of subjects with optimal/normal blood pressures levels at study time represented the "normal population." Results. Normal and reference PWV levels were obtained. Differences in PWV levels and aging-associated changes were obtained. The obtained data could be used to define vascular aging and abnormal or disease-related arterial changes.Entities:
Year: 2012 PMID: 22666551 PMCID: PMC3362057 DOI: 10.1155/2012/169359
Source DB: PubMed Journal: Int J Hypertens Impact factor: 2.420
Clinical and hemodynamic characteristics.
| Group | 10–19 years | 20–29 years | 30–39 years | 40–49 years | 50–59 years | 60–69 years |
|---|---|---|---|---|---|---|
|
| 61 | 103 | 60 | 71 | 66 | 68 |
| Age (years) | 15 ± 2 | 24 ± 2a | 34 ± 2ab | 45 ± 3abc | 54 ± 3abcd | 64 ± 4abcde |
| Anthropometric measurements | ||||||
| Body height (m) | 165 ± 9 | 167 ± 9 | 166 ± 9 | 165 ± 9 | 165 ± 8 | 160 ± 10 |
| Body weight (kg) | 57 ± 11 | 63 ± 12 | 72 ± 16ab | 73 ± 16ab | 71 ± 16ab | 71 ± 12ab |
| BMI (kg/m2) | 21 ± 3 | 23 ± 4a | 26 ± 3ab | 26 ± 3ab | 25 ± 4ab | 27 ± 2ab |
| Peripheral hemodynamics parameters | ||||||
| Systolic pressure (mmHg) | 118 ± 13 | 125 ± 12a | 126 ± 14 | 130 ± 13ab | 132 ± 16abc | 144 ± 19abcde |
| Diastolic pressure (mmHg) | 64 ± 10 | 71 ± 8a | 74 ± 11a | 78 ± 9ab | 79 ± 11ab | 75 ± 10ab |
| Pulse Pressure (mmHg) | 48 ± 6 | 51 ± 8 | 53 ± 10 | 54 ± 8a | 56 ± 9a | 69 ± 13abcde |
| Heart rate (bpm) | 78 ± 13 | 73 ± 11 | 72 ± 8a | 72 ± 12a | 73 ± 12a | 63 ± 10abcde |
| Laboratory | ||||||
| Total cholesterol (mg/dL) | 183.7 ± 32.1 | 172.3 ± 23.3 | 189.3 ± 21.4 | 184.6 ± 17.0 | 217.0 ± 8.6abd | 190.4 ± 20.3 |
| HDL-cholesterol (mg/dL) | 62.1 ± 7.3 | 63.4 ± 13.7 | 66.0 ± 26.6 | 67.4 ± 6.3 | 73.2 ± 19.4ab | 65.2 ± 9.6 |
| LDL-cholesterol (mg/dL) | 101.2 ± 21.2 | 90.1 ± 19.3 | 109.5 ± 28.5 | 100.9 ± 5.8 | 126.9 ± 12.2abd | 91.2 ± 12.1a |
| Triglycerides (mg/dL) | 96.4 ± 47.2 | 83.2 ± 22.4 | 56.2 ± 21.0ab | 58.0 ± 2.0ab | 60.2 ± 21.3ab | 64.2 ± 18.0ab |
Mean value ± SD. N: number of subjects, BMI: body mass index, HDL and LDL: high and low density cholesterol, respectively.
Statistics: a, b, c, d, e : P < 0.05 with respect to 10–19, 20–29, 30–39, 40–49, and 50–59 years, respectively (ANOVA + Bonferroni Test).
Figure 1(a) Algorithms employed to determine the carotid-femoral pulse transit time (PTT): intersecting tangent algorithm (tang) and maximal upstroke during systole (max.up). (b) Distances employed to determine the carotid-femoral PWV. Distance A: direct distance between the carotid and femoral region (direct). Distance B: distance between the sternal notch and the femoral region (sn-fem). Distance C: subtracted distance, obtained as B minus the carotid to sternal notch distance (subtracted). Combing the two PTT algorithms and the three distances, six PWV were quantified: PWVdirect/tang, PWVdirect/max.up, PWVsn-fem/tang, PWVsn-fem/max.up, PWVsubtracted/tang, and PWVsubtracted/max.up. In addition the real PWV was calculated (see text).
PWV levels (reference population).
| All | ||||||
|---|---|---|---|---|---|---|
| 10–19 | 20–29 | 30–39 | 40–49 | 50–59 | 60–69 | |
| PWV direct/tang | ||||||
| Mean | 7.7 | 8.8a | 10.2a,b | 10.7a,b | 11.1a,b | 14.8a,b,c,d,e |
| SD | 1.1 | 1.5 | 1.4 | 1.5 | 1.5 | 5.8 |
|
| 7.2 | 7.7 | 9.1 | 9.6 | 10.2 | 12.5 |
|
| 7.5 | 8.8 | 10.4 | 10.9 | 10.9 | 13.2 |
|
| 8.2 | 9.7 | 11.3 | 11.5 | 11.7 | 13.7 |
|
| 9.0 | 10.8 | 11.7 | 12.5 | 13.1 | 15.1 |
| PWV sn-fem/tang | ||||||
| Mean | 7.7 | 7.7 | 8.6 | 9.5a,b | 9.9a,b,c | 13.1a,b,c,d,e |
| SD | 1.1 | 1.4 | 1.4 | 1.7 | 1.6 | 4.7 |
|
| 7.2 | 6.6 | 7.7 | 8.3 | 8.7 | 10.8 |
|
| 7.5 | 7.6 | 8.9 | 9.5 | 9.5 | 11.5 |
|
| 8.2 | 8.5 | 9.6 | 10.3 | 10.3 | 13.0 |
|
| 9.0 | 9.5 | 10.0 | 11.9 | 12.6 | 14.4 |
| PWV subtracted/tang | ||||||
| Mean | 5.3 | 6.4a | 7.4a,b | 8.0a,b | 8.3a,b | 10.7a,b,c,d |
| SD | 1.2 | 1.4 | 1.3 | 1.6 | 1.5 | 4.0 |
|
| 4.9 | 5.4 | 6.2 | 6.8 | 7.2 | 8.9 |
|
| 5.1 | 6.3 | 7.3 | 7.8 | 7.9 | 9.5 |
|
| 5.6 | 7.3 | 8.2 | 9.0 | 8.7 | 10.3 |
|
| 6.3 | 8.1 | 8.7 | 9.9 | 10.7 | 11.1 |
| PWV direct/max.up | ||||||
| Mean | 7.3 | 8.3a | 9.3a,b | 9.8a,b | 10.2a,b,c | 12.4a,b,c,d,e |
| SD | 0.9 | 1.2 | 1.1 | 1.3 | 1.4 | 2.7 |
|
| 6.9 | 7.4 | 8.3 | 8.9 | 9.3 | 10.9 |
|
| 7.2 | 8.3 | 9.3 | 9.8 | 9.8 | 11.4 |
|
| 7.7 | 9.1 | 10.1 | 10.3 | 11.0 | 12.4 |
|
| 8.5 | 9.9 | 10.5 | 11.5 | 12.4 | 14.4 |
| PWV sn-fem/max.up | ||||||
| Mean | 7.2 | 7.1 | 7.9b | 8.4a,b | 8.8a,b,c | 10.6a,b,c,d,e |
| SD | 0.9 | 1.1 | 0.9 | 1.2 | 1.4 | 2.4 |
|
| 6.9 | 6.2 | 7.0 | 7.5 | 7.9 | 9.3 |
|
| 7.2 | 7.1 | 7.9 | 8.4 | 8.5 | 9.7 |
|
| 7.6 | 7.9 | 8.7 | 9.0 | 9.5 | 10.8 |
|
| 8.1 | 8.6 | 8.9 | 10.0 | 10.7 | 12.3 |
| PWV subtracted/max.up | ||||||
| Mean | 5.0 | 6.0a | 6.7a | 7.1a,b | 7.3a,b | 8.8a,b,c,d |
| SD | 1.0 | 1.1 | 1.1 | 1.2 | 1.4 | 2.0 |
|
| 4.6 | 5.1 | 5.9 | 6.2 | 6.6 | 7.7 |
|
| 4.9 | 5.9 | 6.7 | 6.8 | 7.0 | 8.2 |
|
| 5.2 | 6.6 | 7.3 | 7.8 | 7.7 | 9.1 |
|
| 5.9 | 7.3 | 7.6 | 8.5 | 9.0 | 10.2 |
| PWV real | ||||||
| Mean | 6.1 | 7.2a | 8.2a,b | 8.9a,b | 9.4a,b,c | 12.5a,b,c,d,e |
| SD | 0.9 | 1.3 | 1.2 | 1.6 | 1.8 | 4.3 |
|
| 5.7 | 6.2 | 7.3 | 7.8 | 8.2 | 10.3 |
|
| 6.0 | 7.1 | 8.4 | 8.9 | 8.9 | 10.8 |
|
| 6.5 | 7.9 | 9.0 | 9.5 | 10.1 | 12.1 |
|
| 7.2 | 9.0 | 9.6 | 11.1 | 12.2 | 15.1 |
Statistics: a, b, c, d, e , P < 0.05 with respect to 10–19, 20–29, 30–39, 40–49, and 50–50 years, respectively (ANOVA + Bonferroni).
Figure 2PWV nomograms for the reference population with percentiles (p) 97.5, 50, and 2.5. Broken lines indicate mean confidence interval. The dashed areas illustrate differences between the threshold defined from our population and the fixed unique threshold proposed in the ESH/ESC Guidelines. For PWVReal the fixed unique threshold proposed by Boutouyrie et al. (9.6 m/s) was included [3]. Note that the fixed threshold of PWV = 12 m/s or 9.6 m/s determines an underestimation and overestimation to detect preclinical arterial wall damage in young and old subjects, respectively. Underestimation or overestimation would differ depending on the subjects' age and the algorithm used to assess PWV.
Figure 3PWV thresholds (percentile 97.5) differences considering different combinations of distances and algorithms used to calculate PWV.
PWV thresholds (reference population).
| ≤19 y. | 20–29 y. | 30–39 y. | 40–49 y. | 50–59 y. | 60–69 y. | |
|---|---|---|---|---|---|---|
| PWV direct/max.up | 9.1 | 10.9 | 11.0 | 12.3 | 13.7 | 14.7 |
| PWV direct/tang | 9.8 | 11.7 | 12.5 | 13.5 | 14.2 | 16.5 |
| PWV sn-fem/max.up | 8.9 | 9.1 | 9.4 | 10.7 | 12.2 | 12.6 |
| PWV sn-fem/tang | 9.8 | 10.5 | 10.6 | 12.6 | 13.7 | 16.0 |
| PWV subtracted/max.up | 7.6 | 8.7 | 8.8 | 10.0 | 10.4 | 10.6 |
| PWV subtracted/tang | 8.2 | 9.5 | 10.1 | 11.4 | 11.4 | 12.0 |
| PWV real | 7.9 | 10.0 | 10.1 | 11.8 | 13.6 | 15.6 |
Statistics: regardless the PWV calculus, thresholds differed (P < 0.05) among the different age groups.
PMV levels considering age and blood pressure.
| Blood pressure category | ||||
|---|---|---|---|---|
| Optimal | Normal | High normal | Grades I/II HTA | |
| PWV direct/max.up | ||||
| 10–19 years | 6.9 (5.8–7.9) | 7.4 (5.2–9.6)# | 7.8 (5.9–9.8)#& | (—) |
| 20–29 years | 8.0 (5.6–10.4)a | 8.1 (5.7–10.6)a# | 8.7 (6.8–10.7)a#& | 9.1 (6.1–12.0)#&% |
| 30–39 years | 8.4 (7.7–9.2)ab | 8.7 (5.6–10.5)ab# | 9.7(8.9–10.6)ab#& | 10.4 (9.6–11.2)b#&% |
| 40–49 years | 8.9 (7.2–10.5)abc | 9.6 (8.8–10.0)abc# | 10.0 (7.6–12.5)abc#& | 10.6 (5.6–15.5)b#&% |
| 50–59 years | 9.7 (8.0–11.4)abcd | 9.9 (7.8–12.0)abcd# | 10.4 (6.9–13.9)abcd#& | 10.5 (7.6–13.4)b#& |
| PWV direct/tang | ||||
| 10–19 years | 7.2 (5.9–8.5) | 7.9 (5.0–10.7)# | 8.2 (6.3–10.1)#& | (—) |
| 20–29 years | 8.6 (5.5–11.7)a | 8.7 (5.5–11.9)a# | 9.4 (6.8–12.1)a#& | 10.0 (5.9–14.1)#&% |
| 30–39 years | 9.6 (7.6–11.5)ab | 9.7 (3.5–15.9)ab# | 10.8 (9.6–12.0)ab#& | 11.8 (10.5–13.1)b#&% |
| 40–49 years | 9.8 (7.4–12.1)ab | 10.9 (9.6–12.2)abc# | 11.5 (8.0–15.0)abc#& | 12.5 (7.2–17.9)bc#&% |
| 50–59 years | 10.7 (8.4–13.0) abcd | 11.1 (8.9–13.3)abc# | 11.6 (8.4–14.9)abc#& | 13.0 (8.2–17.2)bcd#&% |
| PWV sn-fem/max.up | ||||
| 10–19 years | 6.8 (5.8–7.9) | 7.2 (5.1–9.3)# | 7.4 (6.2–8.6)#& | (—) |
| 20–29 years | 6.9 (4.8–9.0) | 7.2 (5.4–8.9)# | 7.6 (6.0–9.2)a#& | 7.9 (5.2–10.6)#&% |
| 30–39 years | 7.2 (6.4–8.0)ab | 7.5 (3.6–11.3)ab# | 8.3 (7.5–9.2)ab#& | 8.8 (8.2–9.5)b#&% |
| 40–49 years | 7.6 (5.8–9.5)abc | 8.3 (7.5–9.2)abc# | 8.6 (6.4–10.7)abc#& | 9.3 (4.4–14.1)bc#&% |
| 50–59 years | 8.3 (6.9–9.8)abcd | 8.5 (6.5–10.4)abc# | 8.9 (5.8–12.0)abcd#& | 9.6 (7.6–11.5)bcd#&% |
| PWV sn-fem/tang | ||||
| 10–19 years | 7.2 (5.9–8.5) | 7.6 (5.0–10.3)# | 7.8 (6.1–9.6 )#& | (—) |
| 20–29 years | 7.4 (4.6–10.2)a | 7.6 (5.1–10.1)# | 8.1 (5.7–10.4)a#& | 8.7 (5.0–12.4)#&% |
| 30–39 years | 7.9 (5.7–10.2)ab | 8.7 (7.4–12.8)ab# | 9.2 (8.1–10.4)ab#& | 10.1 (9.0–11.2)b#&% |
| 40–49 years | 8.4 (6.0–10.8)abc | 9.4 (8.3–10.5)abc# | 9.8 (6.7–12.8)abc#& | 10.7 (3.9–17.5)bc#&% |
| 50–59 years | 9.3 (7.2–11.5)abcd | 9.6 (6.8–12.5)abcd# | 10.2 (5.6–14.8)abcd#& | 11.1 (7.6–14.6)bcd#&% |
| PWV subtracted/max.up | ||||
| 10–19 years | 4.6 (3.8–5.4) | 4.8 (3.4–6.3) | 5.0 (4.2–5.8)#& | (—) |
| 20–29 years | 5.7 (3.7–7.7)a | 5.9 (3.2–8.5)a | 6.3 (4.0–8.6)a#& | 6.5 (4.0–9.0)#&% |
| 30–39 years | 6.1 (4.9–7.4)ab | 6.2 (2.8–9.6)ab | 6.9 (6.1–7.8)ab#& | 7.3 (5.4–10.3)b#&% |
| 40–49 years | 6.1 (5.0–7.2)ab | 7.0 (5.9–8.2)abc# | 7.3 ( 5.6–9.0 )abc#& | 7.7 (3.5–12.0)bc#&% |
| 50–59 years | 6.9 (5.7–8.2)abcd | 7.0 (5.3–8.8 )abc | 7.4 (4.7–10.2)abc#& | 8.0 (5.9–9.6)bcd #&% |
| PWV subtracted/tang | ||||
| 10–19 years | 4.8 (3.9–5.8) | 5.1 (3.4–6.9)# | 5.4 (4.3–6.4)#& | (—) |
| 20–29 years | 6.3 (3.5–9.0)a | 6.3 (3.0–9.6)a | 6.8 (3.9–9.7)a#& | 7.1 (3.8– 10.4)#&% |
| 30–39 years | 6.7 (5.2–8.2)ab | 6.9 (2.2–11.6)ab | 7.7 (6.6–8.7)ab#& | 8.4 (7.6–9.3)b#&% |
| 40–49 years | 6.8 (5.2–8.4)ab | 7.7 (6.8–8.7)abc# | 8.2 (5.7–10.7)abc#& | 8.9 (3.0–14.8)bc#&% |
| 50–59 years | 7.8 (6.0–9.5)abcd | 8.0 (5.5–10.5)abcd# | 8.5 (4.5–12.4)abcd#& | 8.8 (5.4–12.2)bc#&% |
| PWV real | ||||
| 10–19 years | 5.8 (4.7–6.8) | 6.3 (4.0–8.5 )# | 6.3 (4.8–7.7) | (—) |
| 20–29 years | 6.9 (4.4–9.4)a | 7.0 (4.4–9.5)a | 7.6 (5.4–9.7)a#& | 8.0 (4.7–11.2)#&% |
| 30–39 years | 7.7 (6.1–9.2)ab | 7.8 (2.8–12.7)ab | 8.6 (7.7–9.6)ab#& | 9.5 (8.4–10.5 )b#&% |
| 40–49 years | 7.8 (6.0–9.7)ab | 8.7 (7.5–10.1)abc# | 9.2 (6.4–12.0)abc#& | 9.9 (7.9–15.7)bc#&% |
| 50–59 years | 8.9 (6.4–11.5)abcd | 9.0 ( 7.6–11.0)abcd# | 9.5 (5.3–13.7)abcd#& | 10.4 (6.9–13.7)bcd#&% |
Statistics: a, b, c, d, e , P < 0.05 with respect to 10–19, 20–29, 30–39, 40–49, and 50–59 years, respectively (ANOVA + Bonferroni).
#, &, %, P < 0.05 with respect to optimal, normal, and high normal blood pressure level, respectively (ANOVA + Bonferroni).